Navigation Links
Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced
Date:4/17/2008

tcome in Alzheimer's disease clinical trials. The ADCS-CGIC is used in Alzheimer's trials to assess clinically relevant overall changes in Alzheimer's disease patients determined by patient and caregiver interviews.

Patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID had fewer behavior-related adverse events during the six-month trial and had a more favorable behavioral outcome as measured by the Neuropsychiatric Inventory, a scale used to measure behavioral problems in Alzheimer's patients. The average change in ADAS-Cog score -- a common cognitive testing measure -- at six months of treatment was numerically improved in patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID than placebo (-0.38 versus +2.61), although this difference did not reach statistical significance in the relatively small number of patients studied.

Levels of Beta-Amyloid (Secondary Endpoints)

Dr. Relkin also reported observations that levels of antibodies against beta-amyloid increased in the cerebrospinal fluid and blood of patients treated with GAMMAGARD S/D and GAMMAGARD LIQUID, while the levels of beta-amyloid in the blood increased. The antibody and beta-amyloid levels were assessed using ELISA immunosorbant assay, a method used to detect antibodies, and observations were analyzed using parametric statistical analysis.

Tolerability

The study also met its endpoint in assessing the tolerability of GAMMAGARD S/D and GAMMAGARD LIQUID in Alzheimer's patients. The only treatment-related adverse events that occurred at a greater frequency with GAMMAGARD S/D and GAMMAGARD LIQUID treatment as compared to placebo were rash and a transient drop in blood count (in most cases, hemoglobin (Hgb) levels returned to within 1 Hgb unit of baseline within three to six months).

Brain Metabolism (Additional, Observational Finding)

Dr. Lisa Mosconi, assistant professor of psychiatry at New York University Medical Center, worked with the New York-Presbyt
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... a new market research report is ... Global Markets and Technologies ... Focus on Routes of Administration ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than ... painless for patients to self-inject prescription drugs in the ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... is expected to grow to $220B by 2018, according ... new type of injector that does not exist today ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) ... the fourth quarter of 2013 on Monday, February 3, ... for release after the close of trading. ... hold a conference call to discuss the operating highlights ... months ended December 31, 2013 on February 3, 2014, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... PRXL ), a leading global biopharmaceutical services ... one of two strategic partners by UCB, a global ... PAREXEL will work with UCB to drive innovation ... and cost effectiveness. The agreement is effective ...
... Reportlinker.com announces that a new market research ... The Outlook for Pharmaceuticals ... http://www.reportlinker.com/p0203103/The-Outlook-for-Pharmaceuticals-in-Central--Eastern-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... Europe is estimated at US$63.6 billion at ...
Cached Medicine Technology:UCB and PAREXEL Sign Strategic Partnership Agreement 2UCB and PAREXEL Sign Strategic Partnership Agreement 3UCB and PAREXEL Sign Strategic Partnership Agreement 4The Outlook for Pharmaceuticals in Central & Eastern Europe 2The Outlook for Pharmaceuticals in Central & Eastern Europe 3The Outlook for Pharmaceuticals in Central & Eastern Europe 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... for the smallest babies, studies show, , , WEDNESDAY, Oct. ... if they might help prevent serious complications and deaths ... results, studies show. , The studies -- one ... the effects of aggressive phototherapy -- found that neither ...
... management, discharge instructions not rated high in survey , , ... U.S. hospitals are not satisfied with their care, Harvard ... patients, experiences, many hospitals were found wanting in key ... fact, almost one-third of patients gave low ratings to ...
... 29 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... discuss third quarter 2008 financial,results and provide a general ... Eastern Time (2:00 p.m. Pacific Time). Financial results,for the ... earlier,that day., Interested parties may ...
... eMatchPhysicians.com Uses Sophisticated Technology to Match Physicians with Hiring Organizations ... ... Aliso Viejo, California (PRWEB) October 29, 2008 -- ... eMatchPhysicians.com , to provide physicians a simple solution to ...
... shopping spree, OAKLAND, Calif., Oct. 29 ... in scrubs, pay for a lot of,medications or ... an,incredibly expensive wardrobe., A new internet game ... Organizing Committee, http://www.DressLikePalin.com, lets web users themselves ...
... the creation of over 2,000 housing opportunities ... ... elected officials,community leaders, and housing and support services professionals gathered,in Duluth ... of creating more than 2,000 housing,opportunities with support services for Minnesota ...
Cached Medicine News:Health News:Two Preemie Treatments May Not Help 2Health News:Two Preemie Treatments May Not Help 3Health News:U.S. Hospitals Lag in Patient Satisfaction 2Health News:U.S. Hospitals Lag in Patient Satisfaction 3Health News:eMatchPhysicians.com Launches to Provide Physicians and Hiring Organizations with a Better Way to Find the Perfect Physician Job 2Health News:eMatchPhysicians.com Launches to Provide Physicians and Hiring Organizations with a Better Way to Find the Perfect Physician Job 3Health News:The Neiman Marxist in the Presidential Race 2Health News:Minnesota Reaches Milestone in Goal to End Homelessness 2
... System supports approaches to Admitting/Discharge/Transfer ... record keeping functions using a ... facilities and cut across institutional ... community clinics, physician, agency, nursing ...
... Dairylands Clinical Information Management ... suite of integrated applications ... departments and automate administrative ... The applications allow organizations ...
... include a Patient Face Sheet, ... many as six custom tabs, ... information is important for you ... Import Manager utility lets you ...
... WEBeDoctor® Physician-office® is an ... physicians, (Solo practice, group ... to complete their normal ... It is a front ...
Medicine Products: